Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Velo3D (VELO) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for Velo3D (VELO) over the last 6 years, with Q3 2025 value amounting to $11.8 million.

  • Velo3D's Cash & Equivalents rose 62339.65% to $11.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.8 million, marking a year-over-year increase of 62339.65%. This contributed to the annual value of $1.2 million for FY2024, which is 9505.18% down from last year.
  • Latest data reveals that Velo3D reported Cash & Equivalents of $11.8 million as of Q3 2025, which was up 62339.65% from $854000.0 recorded in Q2 2025.
  • In the past 5 years, Velo3D's Cash & Equivalents ranged from a high of $296.8 million in Q3 2021 and a low of $854000.0 during Q2 2025
  • Moreover, its 5-year median value for Cash & Equivalents was $24.5 million (2023), whereas its average is $49.1 million.
  • In the last 5 years, Velo3D's Cash & Equivalents soared by 123790.04% in 2021 and then crashed by 9718.39% in 2024.
  • Over the past 5 years, Velo3D's Cash & Equivalents (Quarter) stood at $207.6 million in 2021, then crashed by 84.59% to $32.0 million in 2022, then decreased by 23.42% to $24.5 million in 2023, then crashed by 95.05% to $1.2 million in 2024, then surged by 877.06% to $11.8 million in 2025.
  • Its Cash & Equivalents stands at $11.8 million for Q3 2025, versus $854000.0 for Q2 2025 and $3.9 million for Q1 2025.